COMPARISON
BPC-157 vs Carfilzomib
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
BPC-157 is authorised or registered in 0 and Carfilzomib in 10 of the 10 registers read. BPC-157: highest phase Phase 2. Carfilzomib: highest phase Phase 3 (14 phase 3 trials, 0 with posted results). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| BPC-157 | Carfilzomib | |
|---|---|---|
| Registered trials differs | 4 clinicaltrials.gov · 2026-10-03 | 308 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | Not checked no record of "fdaLabel" for bpc-157 | FDA-approved: KYPROLIS openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for bpc-157 | 2015-11-19 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for bpc-157 | L01XX45 ema · 2026-10-03 |
LEGAL STATUS
Approval in each country read
| Country | BPC-157 | Carfilzomib | Register |
|---|---|---|---|
| United States | Not on the register | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Not on the register | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.